This study examines the 2023 NCCN Guidelines Insights for systemic therapy in stage IV breast cancer, focusing on tumor biology and clinical factors. The updated recommendations reflect the evolving understanding of metastatic breast cancer heterogeneity. By integrating molecular subtype, performance status, and prior therapies, clinicians can tailor treatment strategies to optimize patient outcomes. This review synthesizes the latest evidence and guideline updates, providing a framework for evidence-based decision-making in the management of metastatic breast cancer, and highlights the importance of considering tumor biology in guiding systemic therapy selection.